

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**HST: Setmelanotide for treating obesity caused by LEPR or POMC deficiency**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During consultation we received the following response from NHSE: “This HST could benefit a group of patients that may often not be able to access medical care well with protected characteristics. Both conditions more common in patients who have recessive disorders resulting from consanguineous marriage.” No further issues were identified during the scoping workshop.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The extent to which the above constitutes an issue of equality of access to care in the context of any appraisal is currently unclear. Where appropriate, the committee will consider any potential equality issues identified throughout the evaluation and whether the recommendations make it more difficult for a particular group to access treatment.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix

been made?
No.

**Approved by Associate Director (name):** Nicole Elliott

**Date:** 7/05/2021